A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
收藏DataCite Commons2025-12-16 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012244/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
提供机构：
Vivli
创建时间：
2025-12-16
